Search

everythinglearnresearchcommunity

for

Search:↓

Androgenetic alopecia, a genetic disorder affecting up to 50% of adults, is caused by an excessive response to androgens leading to hair follicle shrinkage. Treatments include FDA-approved drugs, other therapies like low-dose oral minoxidil, and hair transplantation.

Telogen Effluvium is a common hair loss condition, particularly in women, with no specific FDA-approved treatment, and recovery can take up to 18 months.

Platelet-rich plasma can increase hair density and may help treat some skin conditions, but it's costly, not FDA-approved, and needs more research.

Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.

Lavender is widely used for its calming effects and in beauty products, but its medical effectiveness is not fully proven and not FDA-approved.

Exosomes, tiny cell-released particles, may help hair growth, but their exact role is unclear, they're not FDA-approved, and their unregulated use can cause side effects.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Treating alopecia areata is difficult due to limited approved treatments, but new therapies like JAK inhibitors show promise.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Finasteride and minoxidil are approved treatments for hair loss, and hair transplants can be effective but require careful patient selection.

The committee decided not to approve the drug due to low effectiveness and high risks.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Two drugs, finasteride and minoxidil, are approved for hair loss treatment, but new therapies are being developed.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Children with alopecia areata need supportive care and off-label treatments due to a lack of approved options.

The CDC reports 23 measles cases in unvaccinated US kids, new treatments for eosinophilic esophagitis and osteopenia are approved, poor sleep may cause migraines, atopic dermatitis could lead to asthma, migraines might increase Crohn's disease risk, cancer may raise heart disease risk, gout is linked to prostate issues, Cabo Verde is malaria-free, social factors and vitamin D affect dementia risk, smoking increases hair loss risk, certain drugs might lower thyroid disease risk in arthritis, noma is a neglected disease, and meal timing could impact heart health.

New treatments for child hair loss due to immune issues are effective but not yet officially approved.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Female pattern hair loss is common and should be treated early to prevent worsening, with Minoxidil being the main approved treatment.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Lasers and light treatments are now the most common ways to remove hair.

Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.

Certain compounds can boost hair and nail growth.

Aminoacridine and Minoxidil together show promise for better hair and nail growth.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Minoxidil solution and foam both increase hair growth, but the solution works better than the foam.

Deoxycholic acid is effective for reducing chin fat but can cause side effects and serious complications, so careful patient evaluation is needed.

Old psychiatric drugs are increasingly being used for new purposes, and technologies like SmartCube® help create new drugs.